Covid-19 Response Updates from NPHL

Dr. Runa Jha
Director
NPHL

Government of Nepal
Ministry of and Population
Department of Health Services
National Public Health Laboratory

TOTAL NUMBER OF PCR TEST PERFORMED PER WEEK BY DESIGNATED COVID-19



Data source : HEOC sitREP, MoHP (Until 27th Nov 2020)

Government of Nepal
Ministry of and Population
Department of Health Services
National Public Health Laboratory

TOTAL NUMBER OF PCR TEST PERFORMED PER WEEK BY LABS (GOVT / Private)



Data source : HEOC sitREP, MoHP (Until 27th Nov 2020)

Government of Nepal
Ministry of and Population
Department of Health Services
National Public Health Laboratory

TOTAL NUMBER OF PCR TEST PERFORMED PER WEEK BY NPHL



Data source : HEOC sitREP, MoHP (Until 27th Nov 2020)

Government of Nepal
Ministry of and Population
Department of Health Services
National Public Health Laboratory

External Quality Assessment Programme (EQAP)

WHO External Quality Assessment Programme for the Detection of Influenza Viruses by RT-PCR
MIC-PTP-MOL-FLU-WHO-IND-01-P19-2020-11-27-275

World Health Organization
External Quality Assessment Programme
for the Detection of Influenza Viruses by RT-PCR

Panel 19 (2020) --- Individual Report (Final)

Your lab code:	275
Date panel sent: (dd/mm/yyyy)	13/08/2020
Date panel received:	31/08/2020
Date results reported:	11/09/2020
Turn-around time (days):	11 (Received after dispatch period)

Sample	Intended result	Your result	Remarks #
V01-2020	Influenza A(H7)	Influenza A(H7)	
V02-2020	Influenza A(H1)pdm09	Influenza A(H1)pdm09	
V03-2020	Influenza B	Influenza B	
V04-2020	Influenza A(H5)	Influenza A(H5)	
V05-2020	Influenza B	Influenza B	
V06-2020	Influenza A(H9)	Influenza A unsubtypeable [Influenza A positive, H9 not tested]	
V07-2020	Influenza A(H5)	Influenza A(H5)	
V08-2020	Influenza A(H3)	Influenza A(H3)	
V09-2020	Negative	Negative	
V10-2020	Influenza A(H5)	Influenza A(H5)	

OPTIONAL: Genotypic/Phenotypic Antiviral Susceptibility Testing

Sample	Results	Genotypic testing		Phenotypic testing		Remarks'
		Amino acid substitution* (Nucleotide change detected)	Associated with (highly) reduced susceptibility	Oseltamivir	Zanamivir	
A(H1)pdm09 NAB01G-2020	Intended	Mixture of wild type and H275Y (C823T)	Yes	Highly reduced inhibition	Normal inhibition	
NAB01P-2020	Submitted	-	-	-	-	
A(H1)pdm09 NAB02G-2020	Intended	NA- no mutation PA-I38T^	No	Normal inhibition	Normal inhibition	
NAB02P-2020	Submitted	-	-	-	-	
B (Victoria) NAB03G-2020	Intended	Wild type	No	Normal inhibition	Normal inhibition	
NAB03P-2020	Submitted	-	-	-	-	

* Residue position in N1 neuraminidase numbering. (Only results on NA gene are scored. Results on other genes are for educational purpose.)
^ Sample contains PA-I38T mutation associated with reduced inhibition to Baloxavir.

The assessment criteria for results are listed as follows. No remark will be given for correct results.
I. Incorrect results:
(i) Incorrect typing results
(ii) Incorrect subtyping / lineage results [for seasonal influenza A virus samples, an 'unsubtyped' HA result is considered incorrect]
II. False positive results: Reporting 'Positive' results on negative samples
III. False negative results: Reporting 'Negative' results on positive samples if the corresponding typing or subtyping assays were performed
IV. Incorrect NAI susceptibility testing results:
(i) Incorrect genotypic results
(ii) Incorrect phenotypic results

Panel 19 (2020)
27 November 2020
Microbiology Division, Public Health Laboratory Services Branch, CHP, DH

Page 1 of 1

The National Influenza Centre (NIC) at NPHL has *participated* and *passed* the **WHO External Quality Assessment Programme (EQAP)** for the Detection of Influenza Viruses by RT-PCR proficiency test panel 19 (2020).

Hong Kong (27th Nov 2020)

Government of Nepal
Ministry of and Population
Department of Health Services
National Public Health Laboratory

Quality Assurance (Proficiency Test) Panels

- Re-testing strategy
- Distribution of Proficiency Test (PT) panels to *all the **77** designated COVID-19 laboratories* across the country *(with WHO support)*

Government of Nepal
Ministry of and Population
Department of Health Services
National Public Health Laboratory

Trainings (Weekly Virtual sessions)

‘Quality Implementation’

‘Experience sharing on laboratory aspect for COVID-19 response’

Mechi Hospital, Kankai Municipality Hospital, Rapti Academy of Health Sciences (RAHS) and *Bharatpur Hospital COVID-19 Diagnostic Laboratory*

*Participants from different laboratories discussed their challenges and the **WHO consultant** and **NPHL resource person** provided recommendations to address the challenges.*

<u>One on one interaction with COVID-19 labs</u> :

Troubleshooting the issues identified in quality assurance program with support from WHO provided technical support for resolution of quality issues.

Training (Onsite)

Training on Biosafety-Biosecurity and documentation in COVID-19 labs

- Completed training in Lumbini Province
- Ongoing Training at Province 2, Bagmati
- Public as well as private labs participated

Government of Nepal
Ministry of and Population
Department of Health Services
National Public Health Laboratory

Government of Nepal
Ministry of and Population
Department of Health Services
National Public Health Laboratory

Reagent/kit validation

- “High Top” Antigen Kit verified and approved
- iAMP (Atilla Biosystem, USA) & Vivacheck antigen kit received for verification

Hands on training at NPHL

One week refresher training to Microbiologist of Bardibas lab completed

Three week training for pathologist of Mahakali Hospital ongoing

Government of Nepal
Ministry of and Population
Department of Health Services
National Public Health Laboratory

Thank you